NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wells Fargo & Company

NeuroPace (NASDAQ:NPCE – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a note issued to investors on Friday, MarketBeat Ratings reports. They currently have a $9.00 price objective on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 19.05% from the stock’s current price.

A number of other analysts have also commented on NPCE. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Raymond James Financial set a $21.00 price objective on NeuroPace in a research note on Tuesday, September 15th. JPMorgan Chase & Co. downgraded shares of NeuroPace from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $9.00 in a report on Friday. KeyCorp reduced their target price on shares of NeuroPace from $18.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $15.50.

Get Our Latest Stock Report on NeuroPace

NeuroPace Trading Down 37.1%

Shares of NASDAQ:NPCE traded down $4.46 during trading on Friday, reaching $7.56. The stock had a trading volume of 6,104,874 shares, compared to its average volume of 127,272. The company has a debt-to-equity ratio of 4.97, a quick ratio of 3.91 and a current ratio of 4.94. The firm’s fifty day moving average is $13.21 and its 200 day moving average is $14.75. NeuroPace has a 52 week low of $5.46 and a 52 week high of $19.60. The stock has a market cap of $259.46 million, a price-to-earnings ratio of -13.50 and a beta of 1.98.

Institutional Investors Weigh In On NeuroPace

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of NeuroPace in the 2nd quarter worth approximately $39,369,000. First Light Asset Management LLC lifted its stake in NeuroPace by 82.3% in the first quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after purchasing an additional 1,110,484 shares during the last quarter. Deutsche Bank AG purchased a new position in NeuroPace in the second quarter valued at approximately $14,919,000. GSA Capital Partners LLP bought a new position in NeuroPace during the second quarter valued at $1,836,000. Finally, Man Group plc bought a new position in NeuroPace during the second quarter valued at $1,336,000. 78.83% of the stock is currently owned by institutional investors.

Latest NeuroPace News

Here’s some of the latest news about NPCE:

  • Negative Sentiment: Q3 revenue was $23.1 million, below the cited $27.1 million analyst estimate. Revenue from the company’s RNS System grew just 1.4% year over year, signaling limited near-term growth. NeuroPace Q3 results and guidance
  • Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
  • Negative Sentiment: Analyst actions added pressure: JPMorgan cut its rating to neutral and lowered its target from $20 to $9; Wells Fargo and Leerink Partners also downgraded the shares. KeyCorp maintained an overweight rating but cut its target from $18 to $14. Analyst rating changes

About NeuroPace

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

Featured Articles

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.